Abstract: The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.

Abstract: A living body compressing clip 100 includes a clip body 1 with metallic arm parts 5a and 5b configured to hold a living body tissue. The clip body 1 includes compressing pieces 10 that protrude from distal end parts of the arm parts 5a and 5b in a long-side direction of the arm parts 5a and 5b. The compressing pieces 10 are formed from a flexible resin and hold a fluorescent dye. According to the living body compressing clip 100, the compressing pieces 10 causes a vascular network to collapse while holding the living body tissue by the arm parts 5a and 5b. Therefore, when the arm parts 5a and 5b hold the mucosal tissue of the tubular organ and excitation light is applied thereto, the fluorescence emitted by the compressing pieces 10 can be satisfactorily confirmed from the serosal side.

Abstract: The present disclosure provides a humanized antibody that specifically binds to Glypican-1 (GPC-1), and also provides technologies, methods, medicines, and the like related to the humanized antibody. In one aspect, the present disclosure provides a humanized anti-GPC-1 monoclonal antibody that has a high affinity for GPC-1 and has high internalization activity in GPC-1-positive cells. In another aspect, the present disclosure also provides a composition for preventing or treating Glypican-1-positive cancer that includes a complex of a humanized anti-GPC-1 monoclonal antibody and a medicine having cytotoxic activity.

Abstract: Provided is a cranial nerve disorder therapeutic agent that includes, as an active ingredient, a culture supernatant of tissue cells derived from a fetal appendage.

Abstract: Provided is a cranial neuropathy therapeutic agent that contains, as an active ingredient, a culture supernatant for umbilical cord blood monocytic cells.

Abstract: A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

Abstract: A novel anti-tumor agent capable of delivering siRNA or shRNA specifically to pancreatic cancer cells and suppressing tumor growth, invasion, and metastasis of pancreatic cancer is provided. The present invention provides a nucleic acid delivery enhancer for delivering siRNA or shRNA into cells, which consists of a folic acid-cationic oligopeptide complex. The present invention also provides an anti-tumor agent having siRNA or shRNA capable of binding to mRNA or snoRNA expressed in pancreatic cancer cells to inhibit its expression and a folic acid-cationic oligopeptide complex. The siRNA is capable of binding to RNA selected from the group consisting of, for example, SNORA18 snoRNA, NUP85 mRNA, WASF2 mRNA, and SNORA22 snoRNA.

Abstract: The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.

Abstract: An analysis apparatus (100) includes an image acquisition unit (110) and an analysis unit (120). The image acquisition unit (110) acquires image data of a microfossil in a sample collected from a stratum. The analysis unit (120) analyzes the image data acquired by the image acquisition unit (110) using a machine learning result to analyze a taxon or kind of the microfossil in the image data.

Abstract: A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

Abstract: The purpose of the present invention is to produce a chimeric antigen receptor (CAR) specific to glypican-1 (GPC-1) and to treat squamous cell carcinoma with genetically modified cells capable of expressing the CAR. The present invention provides: a chimeric antigen receptor for use in the treatment and/or prevention of squamous cell carcinoma, said chimeric antigen receptor comprising an extracellular domain capable of binding to GPC-1, a transmembrane domain and one or multiple intracellular domains, wherein at least one of the intracellular domains is an intracellular domain containing a primary cytosolic signaling sequence or an intracellular domain containing both a primary cytosolic signaling sequence and a secondary cytosolic signaling sequence; a genetically modified cell capable of expressing the chimeric antigen receptor; and a cell preparation containing the cell.

Abstract: An endoscope includes a scope and an image capturing unit accommodated inside the scope. The image capturing unit includes: first and second prisms; a reflection film provided between oblique faces of the first and second prisms; a first trimming filter on which visible light transmitted through the first prism is incident on the first trimming filter via the reflection film; a first image sensor facing the first trimming filter; a second trimming filter on which near-infrared light transmitted through the second prism being incident on the second trimming filter via the reflection film; and a second image sensor facing the second trimming filter. The first prism is fixed to the second prism, the first trimming filter is fixed to the first prism, and the second trimming filter is fixed to the second prism.

Abstract: The method for diagnosing cerebrospinal fluid hypovolemia includes injecting saline into a subdural space of a subject in a decubitus position, raising an upper body of the subject, and then determining whether the subject has headache or not, or headache of the subject is relieved or not.

Abstract: An endoscope includes a scope and an image capturing unit accommodated inside the scope. The image capturing unit includes: first and second prisms; a reflection film provided between oblique faces of the first and second prisms; a first trimming filter on which visible light transmitted through the first prism is incident on the first trimming filter via the reflection film; a first image sensor facing the first trimming filter; a second trimming filter on which near-infrared light transmitted through the second prism being incident on the second trimming filter via the reflection film; and a second image sensor facing the second trimming filter. The first prism is fixed to the second prism, the first trimming filter is fixed to the first prism, and the second trimming filter is fixed to the second prism.

Abstract: An openable and closable clip for medical use includes a resin clip body, and a fastening ring to be fitted onto the clip body. Clip body includes a pair of opposing arm parts, and connecting part that connects base ends of respective arm parts. Each arm part includes curved part on a base end side, holding part on distal end side, and intermediate part between curved and holding parts. Curved part is curved in arc shape, and intermediate part has a thickness greater than that of curved part. Clip body closes in state where fastening ring is fitted onto clip body on side closer to connecting part than curved part, opens when fastening ring slides onto curved part from connecting part, and closes when fastening ring slides onto intermediate part from curved part. Openable and closable clip can be used in endoscope clip device and opens and closes stably.

Abstract: An electrolyzed water generating apparatus 1 includes: an electrolysis tank D containing a first electrode chamber Da having a cathode 6a, a second electrode chamber Db having anode 6b, and a separating membrane Sp separating the first electrode chamber Da and the second electrode chamber Db from each other; a first water inlet path 4a supplying the first electrode chamber Da with raw water from outside; a first water outlet path 7a carrying to outside hydrogen-containing electrolyzed water generated by electrolysis in the first electrode chamber Da; and a charge amount adjuster 10 for adjusting, during the electrolysis, an amount of electrical charge to be provided to the hydrogen-containing electrolyzed water. The charge amount adjuster 10 adjusts the amount of electrical charge per unit quantity of the generated hydrogen-containing electrolyzed water through control of an electrolytic current or an electrolytic voltage.

Abstract: A medical tool for fingertip of the present invention has a resin layer that emits red fluorescence or near-infrared fluorescence, and is used by putting it on a fingertip. More specifically, the medical tools for fingertip 1A to 1E have a finger cot shape and an opening portion 2 from which the ball of the finger is exposed when put on, and are formed of a resin that emits red fluorescence or near-infrared fluorescence. Alternatively, the medical tools for fingertip 1F and 1G have a globe shape, and a printing layer 8, 9 that is formed of a resin that emits red fluorescence or near-infrared fluorescence on or around the ball of the finger thereof. Further alternatively, the medical tools for fingertip 1H and 1I are a sticker-like medical tool having an adhesive layer provided to one surface of the resin layer that emits red fluorescence or near-infrared fluorescence, and have a size that allows it to be attached to the ball of the finger.

Abstract: An apparatus to determine if a constituent member has been damaged. The constituent member can be a medical product comprising a coating, or a substance kneaded into the product, which emits a fluorescence in the near-infrared region. The apparatus to determine if this constituent member has been damaged includes an irradiation light source, an optical filter, an imaging unit, a display unit and a control unit connected to the light source, the optical filter and the imaging unit to determine and inform that damage has occurred in the constituent member.

Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.

Abstract: The method for diagnosing cerebrospinal fluid hypovolemia includes injecting saline into a subdural space of a subject in a decubitus position, raising an upper body of the subject, and then determining whether the subject has headache or not, or headache of the subject is relieved or not.